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Abstract
NKX2-5 is a homeodomain-containing transcription factor implied in both heart and thyroid development. Numerous
mutations in NKX2-5 have been reported in individuals with congenital heart disease (CHD), but recently a select few have
been associated with thyroid dysgenesis, among which the p.A119S variation. We sequenced NKX2-5 in 303 sporadic CHD
patients and 38 families with at least two individuals with CHD. The p.A119S variation was identified in two unrelated
patients: one was found in the proband of a family with four affected individuals with CHD and the other in a sporadic CHD
patient. Clinical evaluation of heart and thyroid showed that the mutation did not segregate with CHD in the familial case,
nor did any of the seven mutation carriers have thyroid abnormalities. We tested the functional consequences of the
p.A119S variation in a cellular context by performing transactivation assays with promoters relevant for both heart and
thyroid development in rat heart derived H10 cells and HELA cells. There was no difference between wildtype NKX2-5 and
p.A119S NKX2-5 in activation of the investigated promoters in both cell lines. Additionally, we reviewed the current
literature on the topic, showing that there is no clear evidence for a major pathogenic role of NKX2-5 mutations in thyroid
dysgenesis. In conclusion, our study demonstrates that p.A119S does not cause CHD or TD and that it is a rare variation that
behaves equal to wildtype NKX2-5. Furthermore, given the wealth of published evidence, we suggest that NKX2-5mutations
do not play a major pathogenic role in thyroid dysgenesis, and that genetic testing of NKX2-5 in TD is not warranted.
Citation: van Engelen K, Mommersteeg MTM, Baars MJH, Lam J, Ilgun A, et al. (2012) The Ambiguous Role of NKX2-5 Mutations in Thyroid Dysgenesis. PLoS
ONE 7(12): e52685. doi:10.1371/journal.pone.0052685
Editor: Marian Ludgate, Cardiff University, United Kingdom
Received July 24, 2012; Accepted November 19, 2012; Published December 28, 2012
Copyright:  2012 van Engelen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Academic Medical Center (government funding). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: k.vanengelen@amc.uva.nl
¤ Current address: Department of Cell & Developmental Biology, University College London, London, United Kingdom
Introduction
Persistent congenital hypothyroidism of thyroidal origin is
a relatively common disorder, occurring in about 1/2500 live
births [1]. In 85% of cases it is caused by thyroid dysgenesis (TD),
consisting of agenesis, hypoplasia or ectopia of the thyroid gland
[2]. TD is a heterogeneous disorder that occurs mostly sporad-
ically, though 2% of cases are reported as familial [3]. The
pathogenesis of TD is largely unknown; possible roles for
environmental, genetic and epigenetic factors have been sug-
gested, and in a minority of humans with TD mutations in NKX2-1
[4], FOXE1 [5], PAX8 [6] and TSHR [7] have been identified.
Additionally, in a recent study mutations in NKX2-5 were reported
in a small proportion of patients with persistent congenital
hypothyroidism [8].
NKX2-5 encodes a homeodomain-containing transcription
factor that is expressed during thyroid development (for review
see [9]), but it is mainly known to play a crucial role in heart
development [10]. NKX2-5 mutations have been found in
a subset of patients with congenital heart disease (CHD), mostly
septal defects [11,12]. As CHD is overrepresented among
children with TD and vice versa, a developmental association
between the cardiac and thyroid systems has been suggested
[13–15].
We screened families and individual patients with CHD for
mutations in NKX2-5. In this paper we focus on the p.A119S
variation, which we found in two probands. Dentice et al. reported
this as a causative mutation in a child with ectopic thyroid gland,
with functional studies showing a dominant negative effect of the
mutation [8]. We evaluated the heart and the thyroid gland in our
two families with a total of seven p.A119S carriers and we
performed follow-up functional studies. Additionally, we discuss
existing literature on the connection between NKX2-5 mutations
and TD.
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Methods
Ethics Statement
This study was approved by the Medical Ethical Committee of
the Academic Medical Center in Amsterdam. Written informed
consent was obtained from all participants.
Patients and Clinical Evaluation
DNA from 303 patients with primum atrial septal defect (ASDI,
n = 271) or secundum atrial septal defect (ASDII, n= 32) was
extracted from CONCOR, a nationwide registry and DNA bank
for adult patients with CHD, described in detail elsewhere [16].
Additionally, probands of 38 families with multiple (at least two)
affected patients with several forms of CHD, identified at the
departments of clinical genetics or cardiology of the AMC, were
included. In this study, we focused on patients who were found to
carry the p.A119S NKX2-5 variation. Probands with this
variation, as well as their available family members, were clinically
evaluated. Medical records were analyzed and all individuals
underwent physical examination with attention to syndromic
features. Cardiologic examination consisted of a 12-lead electro-
cardiogram (ECG) and two-dimensional echocardiography, which
were assessed by a cardiologist who was blinded for the mutational
status. Thyroid ultrasound and thyroid function analysis were used
to investigate the thyroid gland. TSH and free T4 were measured
by time-resolved fluoroimmunoassay (Delfia, hTSH Delfia Ulta
resp. FT4 Delfia, Perkin Elmer, Turku, Finland), detection limits:
0.01 mU/L for TSH and 2 pmol/L for free T4, total assay
variation: 4–5% for TSH and 6–7% for free T4. Thyreoglobulin
and anti-TPO were measured by chemiluminescence immunoas-
say (LUMI-test Tg resp. anti-TPO, BRAHMS, Berlin, Germany),
detection limits: 1 pmol/L for Tg and 30 kU/L for anti-TPO,
total assay variation: 7–13% for Tg and 8–12% for anti-TPO. The
results of the ultrasound were analyzed by a radiologist who was
blinded for mutational status as well as cardiologic status.
Mutation Analysis
Genomic DNA of CHD patients as well as relatives of patients
carrying the A119S variation was extracted from peripheral blood
according to standard procedures. Coding regions and intron–
exon boundaries of NKX2-5 (NM_004387.3) were analyzed using
direct sequence analysis on an ABI3730xl capillary sequencer
using Big-Dye Terminator v3.1 (Applied Biosystems). Data were
analyzed using Codoncode analysis software (v3.1, CodonCode
Corporation). In the proband with the p.A119S variation who had
aortic coarctation and bicuspid aortic valve, sequence analysis of
the NOTCH1 gene was also performed.
Plasmid Constructs and Transfections
Human clones for NKX2-5 and TBX5 were obtained from the
IMAGE consortium [17]. The human clones were in the following
vectors: pCMVSport6-hNKX2-5 and pcDNA3.1-hTBX5. Pro-
moter construct for ANF-luc is as described before [18], the
promoters for Dio2, Tg and TPO were cloned from their
appropriate species, as described before [8], and subcloned into
pGL3 basic expression vectors (Promega). Expression and pro-
moter constructs were all sequence verified. pCMVSport6-
hNKX2-5 mutants (p.A119S, p.N188K) were constructed using
site-directed mutagenesis (Strategene). Transfections were per-
formed using polyethylenimine (25 kDa, linear, Brunschwick).
EMSA, Probe Annealing
Radioactive Electrophoretic Mobility Shift Assay (EMSA) was
performed using the following wildtype sequence as probes: 59-
TCTGCTCTTCTCACACCTTTGAAGTGGGGGCCTCTT
and its complementary oligo (5’-GCCTCAAGAGGCCCC-
CACTTCAAAGGTGTG), as described before [18], The specific
conditions were as follows: bandshift buffer (BB) (10 mM Tris
pH 7.9, 10% glycerol, 50 mM NaCl, 0.5 mM EDTA); non-
specific competitor Spermidine 3-HCl (Sigma, S2501) at a con-
centration of 1 mg/ml;prepared according manufacturers instruc-
tion. First 5.0 mg crude nuclear cell extracts were pre-incubated
for 5 min at +15 to +25uC in a reaction containing 14 ml BB, 1 ml
of the non-specific competitor spermidine, 1 mg BSA, 1 mM DTT
and supplemented with H20 up to 20 ml. Input was corrected for
Nkx2.5 expression and total amount protein was kept constant at
5.0 mg by addition of empty vector nuclear extracts. Then 2 ml of
labelled Nkx-specific probe (30000 c.p.m) was added. Complexes
were allowed to form for 20–25 min at +15 to +25uC. The samples
were loaded on 6%-TBE polyacrylamide gel which was prerunned
at RT for 30 min at 25 V. Complexes were separated at 4 V/cm
at RT for 60 min. Gels were dried unfixed on Whatman 3 MM
and exposed for autoradiography.
Luciferase Assay
Neonatal rat heart myocytes, immortalized with a temperature-
sensitive SV40 antigen (H10 cells [19], were grown in standard 12-
wells plates in DMEM supplemented with 10% FCS (Gibco-BRL)
and glutamine. HeLa cells were grown according to standard
culturing conditions [20]. 700 ng Nppa/TPO/Dio2/Tg-luciferase
constructs were co-transfected with 1 ng of cmv-renilla vector, as
normalization control (Promega), together with appropriate
combinations of expression constructs (pCMVSport6-hNKX2-5,
pcDNA3.1-hTBX5) up to 900 ng. Measurements were performed
on a Glomax 20/20 luminometer. Triplo transfection experiments
were repeated at least three times for each condition, data were
corrected for intersession variation as described [21]. Statistical
analysis was performed using two-tailed t-test, P,0.05 was
considered significant.
Nuclear Localization
Cos7 cells [22] were seeded in standard 12-wells plates and
transfected with 500 ng WT or p.A119S NKX2.5. 24 h post-
transfection, cells were fixed in 2% paraformaldehyde, permeabi-
lized using 0.3% Triton X-100, and incubated with rabbit anti-
Nkx2-5 (Santra cruz) and DAPI (Sigma).
Results
Mutational Analysis
We identified a total of three missense NKX2-5 variations in
our cohort of 341 CHD patients: a p.C270Y variant in a patient
with ASDI and cleft mitral valve, and twice the p.A119S variant in
separate probands (see below). We will only discuss the results of
the p.A119S variant, as the other variation is outside the scope of
this study.
The nucleotide change from G to T at codon 119 in NKX2-5
was identified in two patients. This results in the substitution of an
alanine for a serine leading to p.A119S. This variation was present
once in a proband from one of the 38 families tested and once in
a proband from 303 sporadic patients with ASD. The p.A119S
variation was not found in 200 local controls. Data from the
NHLBI exome sequencing project shows that it is a very rare
variation with a minor allele frequency of 0.001% (7/6470
individuals, rs1378526) [23]. Alignment of the aminoacids of
proteins of different species shows that this position is conserved up
to rat Nkx2-5 (Figure 1A). However, chicken Nkx2-5 protein
actually has a serine at this position, though the surrounding
NKX2-5 Mutations in Thyroid Dysgenesis
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aminoacids differ. The pedigrees of the families with the p.A119S
variation are shown in Figure 1B. Table 1 summarizes the clinical
features of both families. Analysis of NOTCH1 in the proband of
family 1, who had aortic coarctation and bicuspid aortic valve, did
not show a pathogenic mutation.
Family Phenotypes
Family 1. The p.A119S variation was found in the proband
(I-1), who had an aortic coarctation and bicuspid aortic valve
diagnosed at age 45 years. The coarctation was surgically
corrected at age 45 years and an artificial aortic valve was
implanted at age 73 years because of severe calcification and
stenosis. The probands’ youngest son (II-4) died 20 days after
birth, post-mortem pathology revealing aortic coarctation. The
oldest daughter of the proband (II-1) was born with a ventricular
septal defect (VSD) that closed spontaneously during childhood.
Her oldest daughter (III-1) also had a VSD which was surgically
closed when she was 7 months old. Echocardiography was
normal in the other family members. Normal location, volume
and structure of the thyroid gland were shown by ultrasound in
all investigated family members. Thyroid function was also
normal in all individuals. The p.A119S variation did not
segregate with the cardiac defects within the family, as III-1 is
affected but she does not have the mutation and several family
members without any evidence of CHD carried the mutation
(II-3, III-4, III-5).
Family 2. The p.A119S variation was also found in
a sporadic patient with ASDI with cleft mitral valve as well
as small ASDII, for which a surgical correction took place at
the age of 5 years. Thyroid ultrasound showed normal location
and volume of the gland, but a small nodule was present in the
left lobe. Additionally, anti-TPO antibodies were positive
(620 kU/l) with normal thyroid function tests. These abnormal-
ities are frequent in the general population [24,25], and we
Figure 1. Family pedigrees, aminoacid alignments, nuclear localization of NKX2-5 protein and electro mobility shift assay. A.
Pedigrees of the two families with the p.A119S NKX2-5 mutation. Individuals with congenital heart defects are indicated with a filled black symbol,
while individuals with normal echocardiography are indicated with a white symbol. Grey symbols represent individuals that have not been evaluated
clinically. A slash denotes a deceased individual; the proband is indicated by an arrow. None of the evaluated family members showed thyroid
abnormalities. Heterozygous carriers of p.A119S are represented by +/2 and non-carriers by2/2. B. Multiple alignments of aminoacids of the region
surrounding p.A119 for various species. C. Nuclear localization of either wildtype or p.A119S NKX2-5 protein in COS7 cells. Nuclei are stained in green,
red represents either the wildtype or mutant protein, orange indicates nuclei that are positive for wildtype or mutant protein. D. Electro mobility shift
assay in cos7 cells, using the published nkx2.5 binding site [26]. Wildtype nkx2.5 protein and p.A119S Nkx2.5 protein bind equally well, – is
untransfected control.
doi:10.1371/journal.pone.0052685.g001
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therefore do not consider them to fall outside the range of
expected findings. The probands’ mother was found to carry the
p.A119S variation and the father and brother did not. The
mother was not available for clinical evaluation, though she did
not have a history of cardiac or thyroid disorders. The
probands’ father had a myocardial infarction at age 55. He
did not have CHD. Echocardiography in the probands’ brother
did not show CHD either. Thyroid evaluation of the probands’
father and brother was also normal.
Normal Sub Cellular Distribution of the NKX2-5 p.A119S
Protein
To be able to regulate transcription and exert its function, the
NKX2-5 protein needs to be present in the nucleus. The
localization of the p.A119S NKX2-5 protein was assessed by
transfecting it into rat heart-derived cells (H10) and COS7 cells.
The localization of mutant and WT proteins was visualized with
an antibody against Nkx2-5. Figure 1C shows that both the
wildtype and p.A119S NKX2-5 protein localize exclusively inside
the nucleus, indicating that the process of nuclear import is not
affected by the variation.
No Functional Defect in DNA Binding of p.A119S Nkx2.5
The transcription factor Nkx2.5 activates its target genes by
binding to the DNA. To test whether the DNA binding capacity of
p.A119S Nkx2.5 was altered, we used an electrophoretic mobility
shift assay (EMSA) [18]. A fragment of the Nppa promoter was
used, a well characterized promoter relevant in heart develop-
ment, containing a functional Nkx2.5 binding element [26]. As
shown in figure 1D, both wildtype and p.A119S Nkx2.5 protein
bind equally well, indicating that there is no difference in DNA
binding capacity between p.A119S and wildtype Nkx2.5 protein.
No Difference in Promoter Activations of Wildtype NKX2-
5 or p.A119S NKX2-5
To test the functional consequences of the p.A119S variation in
a relevant cellular context, we used reporter assays in which the
proximal NPPA promoter (2270 to +1) [26], and the Dio2, Tg and
TPO [8] promoters involved in thyroid gland function, were fused
to a luciferase reporter. These promoters all contain functional
binding sites for NKX2-5. We also tested NKX2-5 in combination
with the TBX5 transcription factor as TBX5 synergizes with
NKX2-5 in the activation of the NPPA promoter [26]. These
transactivation assays were performed in both H10 cells and
HELA cells, as used in the original publication of Dentice et al. on
the possible connection between p.A119S and TD [8]. As
a negative control we also used the p.N188K NKX2-5 mutant,
reported as causative in a family with five affected presenting with
atrial septal defects, Ebsteins anomaly and abnormal AV
conduction [27]. No thyroid abnormalities were reported for this
mutation. p.N188K introduces a mutation in the homedomain of
Nkx2.5, an element conserved in all members of the Nkx protein
family and known to directly contact adenine in the major groove
of DNA. The p.N188K mutation leads to a complete loss-of-
function in DNA binding [28] and can therefore serve as a negative
control.
In the H10 cells, the wildtype NKX2-5 and the p.A119S protein
both significantly activated the NPPA promoter driven reporter.
When transfected together with TBX5 both wildtype NKX2-5
and p.A119S NKX2-5 also activated the reporter construct
synergistically (Figure 2A). There was no difference between
wildtype NKX2-5 and p.A119S NKX2-5 in the activation of the
NPPA promoter construct for any condition tested. Likewise, we
observed no difference in activation of the Dio2, Tg or TPO
promoter constructs between wildtype and p.A119S in H10 cells.
We repeated all experiments in HELA cells, and found stronger
activation of all constructs in comparison to the H10 cells.
However, once again, we observed no difference in activation of
any promoter tested between wildtype NKX2-5 and p.A119S
NKX2-5 (Figure 2B).
Discussion
In our population of 303 patients with ASD and 38 probands
from families with CHD, we found the NKX2-5 p.A119S
variation in two patients. The variation did not segregate with
CHD in the familial case, nor were any signs of TD present in the
seven mutation carriers. Furthermore, functional studies showed
no difference between wildtype and p.A119S protein in activation
of four different promoters in either H10 cells or HELA cells.
Taken together, our results strongly suggest that the p.A119S
variation behaves similar to wild type NKX2-5 and that it has no
discernible pathogenic role in either CHD or TD.
NKX2-5 belongs to the NK-2 family of homeodomain-contain-
ing transcription factors, which are conserved from flies to humans
[10]. Its role as a transcription regulator during early embryonic
heart developmental has been known for many years, and
mutations in NKX2-5 are found in patients with CHD [10–12].
NKX2-5 has also been shown to be required for thyroid
development in animal studies [8,29]. The link between thyroid
development and NKX2-5 was highlighted by a recent publication
of Dentice et al. [8], who reported three variations in NKX2.5 in
four of the 241 patients with persistent congenital hypothyroidism
studied, amongst them the p.A119S variation. They performed
functional studies and showed a reduced DNA binding capacity
and reduced transactivation properties with a dominant negative
effect for p.A119S in comparison to wildtype Nkx2-5. The
p.A119S mutation identified by Dentice et al. occurred in a girl
with an ectopic thyroid gland. Her mother, who also carried the
mutation, had auto-immune hypothyroidism but no evidence of
TD and both were without evidence of CHD. Our molecular
testing of the p.A119S variation in both rat heart derived (H10)
cells and HELA cells showed no difference in transactivation of
any of the four promoters tested (NPPA, Tg, Dio2, TPO), which is in
contrast to the results obtained by Dentice et al. Nevertheless, the
results of our functional studies are in agreement with our clinical
data as the mutation did not segregate with CHD in our familial
case and none of our seven mutation carriers had thyroid disease.
Moreover, the A119S variation is present in the general
population at a low rate (0.001%) and classified as a SNP [23].
In general, we conclude that we cannot uphold the results
obtained by Dentice et al., and it is unclear why the molecular
results between the two studies are different, as the same proteins,
promoters and cell lines were used. One difference is the fact that
we did include a negative control (p.N188K) to show that our
assay is robust and no confounding variables acted on the
experiment.
Given the above, an important question is to what extent
NKX2-5 mutations are involved in the pathogenesis of TD. In
addition to p.A119S, three other NKX2-5 variations have been
reported in literature thus far to be associated with TD: p.R25C,
p.S265R and p.R161P [8,30]. The p.R25C variation has been
identified in several patients with CHD, none of whom were
reported to have TD [31]. Moreover, this variation is present in
1% of the general population as a SNP (rs2893667) [23], making it
unlikely that it plays any pathogenic role in TD. In contrast, both
the p.S265R and the p.R161P variation have not been reported in
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the general population. The p.S265R variation was reported in
a girl with TD who also carried a mutation in the PAX8 promoter
region [30] and the mutant protein was shown to have a reduced
function. However, as the girls’ healthy brother, father and
grandmother also carried the NKX2-5 variation and the PAX8
mutation may have accounted for TD in the girl, there is no direct
evidence that the p.S265R variation causes TD. The p.R161P
NKX2-5 variation was found in a TD patient; however her father
also carried the mutation but had no TD or CHD. Taken
together, none of the four currently published NKX2-5 variations
have been demonstrated to segregate with a phenotype of TD
within a family. Although incomplete penetrance cannot be totally
excluded, there is no strong genetic evidence of a clear pathogenic
effect of the mutations.
To gain further insight into the role of NKX2-5 mutations in
TD, a cohort of TD patients can be investigated for mutations in
NKX2-5. However, the NKX2-5 gene has been analyzed in over
460 congenital hypothyroidism patients to date, but no additional
mutations were identified (Table 2) [14,15,32–35]. Interestingly,
51 of these patients also had CHD [14,33]. Furthermore, none of
the more than 150 CHD patients with a demonstrated NKX2-5
mutation [12] were reported to have thyroid problems.
Although there is a lack of evidence for a strong pathogenic
effect of NKX2-5 mutations in human TD, Nkx2-5 has been
shown to be involved in thyroid development. Evidence for this
comes from studies using wildtype Nkx2-5 mice, showing Nkx2-5
expression in the thyroid primordium up to E11.5 [8]. Moreover,
Nkx2-5 knockout mice demonstrate thyroid bud hypoplasia
[8,28]. Although these studies suggest that absence of Nkx2-5
could lead to (a form of) TD, one should keep in mind that these
observations are based on Nkx2-5 null mice, which die around E9-
10 [36]. In contrast, heterozygous knockout mice are viable and
are not reported to have TD [37]. This suggests that the loss of one
Nkx2-5 allele is tolerated, perhaps by compensation during
development by paralogue genes such as NKX2-1, which activates
the same promoter regions as NKX2-5.
Altogether, given the wealth of published evidence, we believe
that NKX2-5 mutations do not play a major pathogenic role in
TD. A role of NKX2-5 as a genetic modifier cannot entirely be
excluded though. To our opinion, there is currently not enough
evidence to warrant routine genetic testing for NKX2-5 mutations
Figure 2. Relative activation of the Nppa, Dio2, Tg and TPO promoters in combination with wildtype NKX2-5, p.A119S NKX2-5,
p.N188K NKX2-5 or TBX5. A. In H10 cells. B. In HELA cells. Significant differences between vector and condition tested are marked with *, P,0.05.
# denotes a significant difference between conditions tested with and without TBX5, P,0.05. Error bars represent standard deviation (SD). Each
condition has been tested at least in three independent triplicate experiments.
doi:10.1371/journal.pone.0052685.g002
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in TD patients, and vice versa, to evaluate the thyroid in
individuals carrying an NKX2-5 mutation.
In conclusion, the results of our study demonstrate that p.A119S
does not cause CHD or TD and that it is a rare variation that
behaves equal to wildtype NKX2-5. Furthermore, given the lack
of clear evidence of pathogenicity of the reported NKX2-5
mutations, the high amounts of patients with TD without an
NKX2-5 mutation and the absence of TD in NKX2-5 mutation
carriers, we suggest that NKX2-5 mutations do not play a major
pathogenic role in thyroid dysgenesis and that genetic testing for
NKX2-5 in TD is not warranted. A role of NKX2-5 as a genetic
modifier cannot entirely be excluded.
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